How do you decide on adjuvant therapy in a patient with a Stage IA uterine carcinosarcoma without any myometrial invasion?

The NCCN recommends either systemic therapy + brachytherapy or pelvic RT + brachy or brachy alone or observation. How do you decide among these options? Does your recommendation change if there is invasion but < 50%?

1 Answer

Mednet MemberInvited Expert

Radiation Oncology · Varian Medical Systems/Allegheny health network

Answered on · Updated on

There is no good prospective study. Our approach, based on outcome and retrospective data (including NCDB), is brachy plus chemo.

https://www.ncbi.nlm.nih.gov/pubmed/30170976

This is paper I was referring to. With all the caveats of NCDB studies, it givess some objective information where prospective data is lacking

Join for free or sign in to see the full answer